At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 28 enrolled
Drug / intervention
Duloxetine +2 moredrug
Likely dose
Duloxetine 60 mg orally once dailyAI-extracted
Key inclusion· 5
- ✓Age >18 years, outpatient status
- ✓Primary diagnosis of generalized social anxiety disorder per DSM-IV criteria
- ✓LSAS (Liebowitz Social Anxiety Scale) score >50
- ✓No clinically significant abnormalities on physical exam, ECG, or lab work
Key exclusion· 11
- ✕History of intolerance or lack of response to prior duloxetine trial at highest tolerated dose <120 mg/day
- ✕Acute narrow-angle glaucoma
- ✕Pregnant, lactating, or women of childbearing potential not using medically accepted contraception
- ✕Concurrent psychotropic medications; benzodiazepines/antidepressants must be discontinued ≥1 week before baseline (≥5 weeks for fluoxetine)
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Duloxetine for Social Anxiety Disorder: Prediction of Long Term Outcome
In Brief
A Phase 3 clinical trial evaluating Duloxetine and Placebo for Anxiety Disorder. Completed, enrolled 28 participants across 1 site.
Detailed Summary
The purpose of this study is to examine the safety and efficacy of duloxetine for the treatment of social anxiety disorder.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAnxiety Disorder
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJun 2004
First PostedJun 2005
Primary CompletionNov 2008
Study CompletionJul 2010
TodayJul 2026
First PostedJun 14, 2005
Enrollment StartJun 1, 2004
Primary CompletionNov 1, 2008
Study CompletionJul 1, 2010
TodayJul 2, 2026
Enrollment to primary: 4.4 yearsPosted 21.1 years ago
Interventions
Duloxetinedrug
60 mg duloxetine 1x per day
Duloxetinedrug
60 mg duloxetine 1x per day + 60mg duloxetine 1x per day
Placebodrug
60mg placebo 1x per day